Share Name Share Symbol Market Type Share ISIN Share Description
Shield Therapeutics Plc LSE:STX London Ordinary Share GB00BYV81293 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.00 1.04% 97.00 97.00 105.00 101.00 101.00 101.00 37,407 16:35:22
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.7 -9.1 -8.0 - 114

Shield Therapeutics PLC Investor Presentation

06/03/2020 7:00am

RNS Non-Regulatory


Shield Therapeutics PLC

06 March 2020

Shield Therapeutics plc

("Shield" or the "Group")

Shield Therapeutics to present at the Hardman & Co. Investor Forum

London, UK, 6 March 2020: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru (R) /Accrufer (R) (ferric maltol), will be presenting at the Hardman & Co. investor forum, providing an overview of the business and the progress being made by the Company.

Carl Sterritt, Chief Executive Officer, will present at the Hardman & Co. investor forum on Tuesday 10 March 2020 at Howard Kennedy LLP, 1 London Bridge, London, SE1 9BG starting from 5.30pm. The event brings together high net worth investors and private investors with an interest in growth stocks. The evening will comprise of each company presenting for 10 to 15 minutes followed by an opportunity for Q&A.

No new material information will be disclosed at either event and t he presentations will be made available on the Company website shortly after the events here:

For further information please contact:

 Shield Therapeutics plc                    
 Carl Sterritt, Chief Executive 
  Officer                                                   +44 (0)20 7186 8500 
 Tim Watts, Chief Financial 
   Nominated Advisor and J oint 
 Peel Hunt LLP 
 James Steel/Dr Christopher 
  Golden                                                    +44 (0)20 7418 8900 
   Joint Broker 
   finnCap Ltd 
   Geoff Nash/Matt Radley/Alice 
   Lane                                                     +44 (0)20 7220 0500 
  Financial PR & IR Advisor 
 Walbrook PR                       +44 (0)20 7933 8780 or 
                                          +44 (0)7980 541 893 / +44 (0)7584 391 
 Paul McManus/Lianne Cawthorne                                              303 

About Shield Therapeutics plc

Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives . The Group's lead product, Feraccru (R) / Accrufer (R) has exclusive IP rights until the mid-2030s and is approved for the treatment of iron deficiency with or without anaemia in adults in the European Union, the United States and Switzerland. In Europe it is marketed as Feraccru (R) with commercialisation led by Norgine BV and in the USA the product will be marketed as Accrufer (R) with Shield currently in the process of selecting a commercialisation partner. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co. Ltd for the development and commercialisation of Feraccru(R)/Accrufer(R) in China, Hong Kong, Macau and Taiwan.

For more information please visit

About Feraccru (R) /Accrufer(R)

Feraccru (R) /Accrufer(R) is a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia that has been shown to be an efficacious and well-tolerated therapy in a range of controlled phase 3 trials, including positive results from the Phase IIIb AEGIS-H2H study in which Feraccru (R) /Accrufer(R) demonstrated it was non-inferior in delivering improvements in haemoglobin levels compared to intravenously-administered (IV) Ferinject(R)/Injectafer(R) (ferric carboxymaltose). Feraccru (R) /Accrufer(R) therefore offers a compelling alternative to IV iron for those patients unable to tolerate salt-based oral iron therapies and wish to avoid the complexities of infusion-based iron therapies.

When salt-based oral iron therapies are ingested they can cause a range of mild-to-severe gastrointestinal tract (GI) adverse events, including nausea, bloating and constipation through the release and subsequent reactivity of free iron in the GI tract, leading to poor tolerability, reduced patient compliance and ultimately treatment failure. Feraccru (R) /Accrufer(R) is not an iron salt and, as a result, it does not routinely cause the same treatment-limiting intolerance issues of salt-based iron therapies, whilst the iron from the ferric maltol molecule can be readily absorbed.

Prior to Feraccru (R) /Accrufer(R) , IV iron therapies were the only realistic alternative treatment option for iron deficient patients with or without anaemia intolerant of or unwilling to be treated salt-based oral iron therapies. However, use of such an invasive, costly, inconvenient and complex to administer treatment option, which is associated with potentially life-threatening and spontaneous hypersensitivity reactions, means there remains a clear unmet medical need for these patients to have access to an effective therapy that is well tolerated, convenient and does not require hospital-based administration. Feraccru (R) /Accrufer(R) meets those requirements.

About Iron Deficiency

The WHO states that iron deficiency is the most common and widespread nutritional disorder in the world. As well as affecting a large number of women and children in non-industrialized countries, it is the only nutrient deficiency which is also significantly prevalent in virtually all industrialised nations. There are no current global figures for iron deficiency but, using anaemia as an indirect indicator, it can be estimated that most preschool children and pregnant women in non-industrialised countries, together with at least 30-40% in industrialized countries, are iron deficient.

Forward-Looking Statements

This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations and include statements related to the commercial strategy for Feraccru(R)/ Accrufer(R) These statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties, many of which are beyond our control, that may cause actual results, performance or achievements to be materially different from management's expectations expressed or implied by the forward-looking statements, including, but not limited to, risks associated with, the Group's business and results of operations, competition and other market factors. The forward-looking statements made in this press release represent management's expectations as of the date of this press release, and except as required by law, the Group disclaims any obligation to update any forward-looking statements contained in this release, even if subsequent events cause our views to change.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit



(END) Dow Jones Newswires

March 06, 2020 02:00 ET (07:00 GMT)

1 Year Shield Therapeutics Chart

1 Year Shield Therapeutics Chart

1 Month Shield Therapeutics Chart

1 Month Shield Therapeutics Chart
ADVFN Advertorial
Your Recent History
Shield The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200605 00:28:46